Flatiron Health

Cancer is global. The data researchers use to understand it should be, too. Flatiron Telescope is expanding internationally, bringing real-world data from the UK, Germany and Japan into the same AI-powered oncology intelligence platform as the US. With a database representing more than six million patients, life sciences teams can explore how patient populations, treatment patterns and clinical practice differ across markets, assess study feasibility, and move from a research question to an actionable patient cohort faster. And they can do it through natural-language questions, without writing code. See what’s possible: https://lnkd.in/dUTNWNhd/?utm_campaign=Conference:ESMO2026Pre-eventSingleImageAds(GlobalEvidence)&utm_source=linkedin&utm_medium=paid&utm_id=1232047934&hsa_acc=506620034&hsa_cam=1232047934&hsa_grp=903216354&hsa_ad=1605760484&hsa_net=linkedin&hsa_ver=3

40+ hospitals and practices trust Flatiron Health in Germany. 🌐 Why? Because we transform their data into scientifically and clinically actionable real-world evidence. Our network across 8 federal states already processes 80,000+ patient records today, curated from structured and unstructured data with clinical depth and consistent quality. This is the exact standard required for researching and developing more effective therapies: • Longitudinal and deeply clinical • Reflects everyday care through direct EHR integration • High-quality, verified data quality • Tumor-specific, fit-for-purpose data models • Actionable insights via user-friendly RWE intelligence platform Find out more: https://lnkd.in/duSdRbYX/?utm_campaign=Conference:ESMO2026Pre-eventSingleImageAds(GlobalEvidence)&utm_source=linkedin&utm_medium=paid&utm_id=1232047934&hsa_acc=506620034&hsa_cam=1232047934&hsa_grp=903216354&hsa_ad=1605734754&hsa_net=linkedin&hsa_ver=3

How can patients’ experiences across countries help us better understand cancer care? At #ESMO26 in Madrid, 17 research abstracts feature Flatiron Health data, including four studies examining treatment patterns, effectiveness, and outcomes across colorectal, lung, and prostate cancer. Our research explores: - How treatment approaches for metastatic colorectal cancer differ across Germany, Japan, and the UK - The association between serum sodium levels and outcomes in patients receiving immunotherapy for metastatic lung cancer - How a colorectal cancer treatment combination performs in everyday US practice - Gaps in prostate cancer treatment sequencing and diagnostic testing Together, these studies show how real-world data can help answer questions beyond clinical trials and identify opportunities to improve care. https://lnkd.in/d42ypsmD/?utm_campaign=Conference:ESMO2026Pre-eventSingleImageAds(GlobalEvidence)&utm_source=linkedin&utm_medium=paid&utm_id=1232047934&hsa_acc=506620034&hsa_cam=1232047934&hsa_grp=903216354&hsa_ad=1605705124&hsa_net=linkedin&hsa_ver=3

Two times more patients. Three new geographies. One consistent data model. Flatiron Health has expanded its global Panoramic datasets with AI-powered breast cancer and NSCLC real-world data across the UK, Germany, and Japan—the second multinational Panoramic launch, following January's prostate cancer debut. Built on the same common data model underpinning Flatiron's US breast cancer and NSCLC Panoramic datasets—spanning nearly 1.5M patients—these new datasets unlock 2x the patients previously available across both tumor types and geographies, validated against Flatiron's VALID framework and built by clinical teams local to each market. For HEOR, RWE, and Medical Affairs teams, that means consistent cohorts and comparable outcomes across markets—complexity turned into clarity, ahead of ESMO 2026. Learn more about the datasets: https://lnkd.in/d4sZheua/?utm_campaign=Conference:ESMO2026Pre-eventSingleImageAds(GlobalEvidence)&utm_source=linkedin&utm_medium=paid&utm_id=1232047934&hsa_acc=506620034&hsa_cam=1232047934&hsa_grp=903216354&hsa_ad=1605655574&hsa_net=linkedin&hsa_ver=3

Life sciences teams using real-world oncology evidence can now learn from even more countries and patients with cancer. With rapid site expansion, Flatiron's international network now spans 160K+ patients across the UK, Germany, and Japan, and counting. Register to meet us at #ESMO26 to see how our global scale can strengthen your evidence strategy.

See how you can power multinational feasibility analyses and comparative effectiveness and clinical outcomes research with answers sourced from Flatiron’s EHR-derived oncology RWD. Register for a live demo of Flatiron Telescope, an AI-powered intelligence platform, at #ESMO2026 to explore international data from the US, UK, Japan, and Germany.